ATOSSA THERAPEUTICS, INC. ATOS Income Statement

Atossa therapeutics, inc. (ATOS)

Income statement / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Sep'11
Diagnostic testing services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	-	-	-	-	-	-
Product sales
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	-	-	-	-	-	-
Diagnostic testing service
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	591	475	376	0	0	0
Product sales
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17	6	6	0	0	0
Net revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	2	6	16	40	84	157	474	632	683	712	609	481	383	0	0	0
Diagnostic testing services
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	58	105	81	64	80	35	29	0	0	0
Product sales
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	220	239	238	238	18	0	0	0	0	0
Cost of revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	30	56	279	345	320	303	99	35	29	0	0	0
Loss on obsolete inventory
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	0	-	-
Loss on Reduction of Inventory to LCM
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Gross profit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6	16	40	-96	-49	45	137	363	403	504	416	323	0	0	0
Operating expenses
Selling expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,421	1,140	923	803	695	1,036	1,127	1,223	1,257	1,150	864	668	466	281	0	0	0
Research and development
6,132	6,645	6,596	6,334	5,190	4,209	3,577	2,898	2,254	2,328	2,477	1,819	1,164	770	875	1,739	1,943	2,359	1,142	1,116	1,253	1,110	2,230	1,628	1,307	1,105	1,196	1,423	1,776	1,974	0	0	0	-
General and administrative
10,005	10,620	10,158	10,433	8,433	7,224	7,280	6,706	5,103	4,859	4,819	4,979	5,460	6,479	6,841	7,763	8,663	8,846	8,982	8,630	8,638	8,052	8,238	9,053	8,768	8,558	7,749	5,481	4,007	3,044	621	0	0	0
Total operating expenses
16,138	17,265	16,755	16,767	13,624	11,434	11,320	10,066	7,820	7,649	8,016	7,518	7,344	7,968	7,950	10,234	11,682	12,627	13,616	13,022	13,048	12,211	11,504	11,808	11,299	10,921	10,095	7,769	6,453	5,485	2,412	0	0	0
Operating loss
-16,138	-17,265	-16,755	-16,767	-13,624	-11,434	-11,320	-10,066	-7,820	-7,649	-8,016	-7,518	-7,344	-7,968	-8,081	-10,365	-11,813	-12,758	-13,614	-13,016	-13,032	-12,171	-11,600	-11,857	-11,254	-10,784	-9,732	-7,365	-5,948	-5,069	-4,637	0	0	0
Change in fair value of common stock warrants
-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Warrant financing expense
-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other income (expense)
-	-	-	-	-	-	-	-	-	-	-163	1,599	1,599	1,599	1,646	-46	1	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Other expense
24	25	55	43	20	29	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-
Interest income
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0	1	3	0	0	0
Interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	0	0	8	10	12	12	0	0	0
Loss before income taxes
-	-	-	-	-	-	-	-	-	-	-	-6,264	-5,744	-6,368	0	0	0	-	-13,495	-12,967	-13,033	-12,170	-11,602	-11,859	-11,254	-10,784	-9,732	-7,374	-5,958	-5,079	-4,646	0	0	0
Loss before income taxes
-16,113	-17,239	-16,699	-16,723	-13,603	-11,404	0	0	0	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income taxes
-	-	-	-	-	-	-	-	0	-	0	-	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Loss from operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-11,811	-12,758	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,002	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-16,113	-17,239	-16,699	-16,723	-13,603	-11,404	-11,319	-10,194	-8,293	-8,122	-8,653	-6,264	-5,744	-6,368	-8,806	-13,329	-14,752	-15,760	-16,611	-15,539	-15,581	-14,657	-11,602	-11,859	-11,254	-10,784	-9,732	-7,374	-5,958	-5,079	-4,646	0	0	0
Deemed dividend attributable to preferred stock
-	-	-	-	-	-	-	0	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deemed dividends attributable to preferred stock
-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss applicable to common shareholders
-	-	0	0	-	-	0	0	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss per common share from continuing operations - basic and diluted (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-2.04	-	-0.13	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss per common share from discontinued operations- basic and diluted (in dollars per share)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.30	-	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss per common share - basic and diluted (in dollars per share)
-0.32	-0.25	-0.36	-0.80	-0.62	8.70	-0.64	-5.08	-8.48	4.26	-2.11	-7.72	-5.40	-0.58	0.07	-0.67	-0.98	-	-	-0.11	-0.13	-0.25	-0.13	-0.13	-0.10	-0.17	-0.22	-0.17	-0.14	-0.12	-0.10	-0.10	-0.09	-0.11
Weighted average shares outstanding - basic and diluted (in shares)
9,130	9,166	9,130	9,126	6,565	8,152	5,183	3,073	220	1,926	1,034	623	315	3,794	3,024	2,587	2,382	-46,868	1,845	27,686	24,916	22,767	24,537	24,430	24,419	17,877	15,830	14,808	13,421	16,041	11,256	11,256	11,256	11,256